Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605536856 | ||
| 003 | CHVBK | ||
| 005 | 20210128100854.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-3100-9 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-3100-9 | ||
| 245 | 0 | 0 | |a Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine |h [Elektronische Daten] |c [V. Gmiro, S. Serdyuk, O. Veselkina] |
| 520 | 3 | |a Adamantane-containing glutamate blocker IEM-1913 (1-amino-4-(1-adamantane-amino)-butane dihydrochloride) equals to memantine in antiparkinsonian potency, but surpasses it in anticonvulsive, antidepressant, and analgesic activities. Moreover, its use is less toxic and safer. IEM-1913 produces significant pharmacological effects at a wide concentration diapason (0.03-1.00 mg/kg), while memantine is effective within a narrow range only (15-20 mg/kg). High pharmacological efficacy and low toxicity of IEM-1913 can be explained by the fact that in contrast to monocationic selective NMDA antagonist memantine, the dicationic glutamate blocker IEM-1913 produces a combined block of cerebral NMDA and AMPA receptors. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a NMDA |2 nationallicence | |
| 690 | 7 | |a AMPA |2 nationallicence | |
| 690 | 7 | |a IEM-1913 |2 nationallicence | |
| 690 | 7 | |a memantine |2 nationallicence | |
| 690 | 7 | |a parkinsonism |2 nationallicence | |
| 700 | 1 | |a Gmiro |D V. |u Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Serdyuk |D S. |u Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | |
| 700 | 1 | |a Veselkina |D O. |u Verteks, St. Petersburg, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 68-71 |x 0007-4888 |q 160:1<68 |1 2015 |2 160 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-3100-9 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-3100-9 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gmiro |D V. |u Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Serdyuk |D S. |u Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Veselkina |D O. |u Verteks, St. Petersburg, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 160/1(2015-11-01), 68-71 |x 0007-4888 |q 160:1<68 |1 2015 |2 160 |o 10517 | ||